
QIAGEN and INOVIO Pharmaceuticals have extended their collaboration to develop a new diagnostic test which identifies the women most likely …

The FDA has put bluebird bio’s LentiGlobin gene therapy programme for sickle cell disease (SCD) on clinical hold, following Suspected …

RedHill Biopharma has announced its plans to expand the company’s global Phase II/III study of opaganib in patients with severe …

UCB and Microsoft have agreed a new multi-year collaboration to discover new medicines by combining UCB’s drug discovery and development …

Otonomy’s OTIVIDEX treatment for Meniere’s disease has failed to meet its primary endpoint in its Phase III trial, the company …

Novo Holdings has agreed a deal to buy Canadian pharmaceutical research company Altasciences from Audax Private Equity, the two companies …

The European Commission (EC) has granted marketing authorisation Dynavax Technologies Corporation’s HEPLISAV B vaccine for the active immunisation against hepatitis …

The FDA has approved Regeneron & Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small …

GlaxoSmithKline (GSK) and Sanofi are set to begin a new Phase II study of their COVID-19 vaccine candidate, following setbacks …

ONK Therapeutics and blood cancer charity Anthony Nolan will work together on therapies for patients with haematological malignancies (blood cancers) …

MaxiVAX and Minaris Regenerative Medicine have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of …

AstraZeneca will voluntarily withdraw the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or …

The MHRA has granted marketing authorisation in the UK for Seagen’s TUKYSA (tucatinib) in combination with trastuzumab and capecitabine, for …

In the last week, a number of COVID-19 new vaccine developments have been made. Pfizer and BioNTech’s vaccine has proven …

Cell Guidance Systems’ new POlyhedrin Delivery System (PODS) technology has been shown to have therapeutic potential in the treatment of …

Cascade Chemistry, a leading pharmaceutical contract development and manufacturing organisation, has initiated the $14 million construction of new facilities to …

Dermavant Sciences has announced positive safety and efficacy results from a planned interim analysis of PSOARING 3, a long-term, open-label …

RedHill Biopharma has announced agreements with Cosmo Pharmaceuticals to manufacture two of RedHill’s key products. Cosmo will manufacture Movantik, RedHill’s …

Onward Therapeutics and Biomunex Pharmaceuticals have signed a co-development agreement of a bi-specific antibody for cancer patients.

Nektar Therapeutics has announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin (BEMPEG), an investigational CD122-preferential …